This summit gathers executives and scientific experts from international pharmaceutical companies across discovery, preclinical, clinical, regulatory, and commercial disciplines to help shape the future of ALS drug development.

Our Head of Pharmacology, Dr. Jonathan van Eyll will be attending the 2-day conference and be available for 1-1 meetings to share our progress towards a new therapeutic approach selectively targeting HDAC6 inhibition for the potential treatment of ALS.

In February 2024, we announced a collaboration with The ALS Association through the Lawrence and Isabel Barnett Drug Development Program, aiming at profiling our novel HDAC6 lead candidates in efficacy and safety studies.

HDAC6 as a promising and innovative therapeutic target for the treatment of ALS originates from the groundbreaking research of our scientific founder Professor Ludo Van Den Bosch at the VIB-KU Leuven Center for Brain & Disease Research, in closed collaboration with Professor Philip Van Damme, MD from the University Hospital in Leuven and the Leuven Center for ALS (LEUCALS).

For more information on the event: Click here